<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02967731</url>
  </required_header>
  <id_info>
    <org_study_id>480MFSDD2016-001</org_study_id>
    <nct_id>NCT02967731</nct_id>
  </id_info>
  <brief_title>480 Biomedical Sinus Drug Depot</brief_title>
  <official_title>An Exploratory Safety Study of 480 Biomedical Sinus Drug Depot in Adult Subjects With Chronic Sinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>480 Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>480 Biomedical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, exploratory safety study of the 480 Biomedical Mometasone Furoate Sinus
      Drug Depot in adult subjects with chronic sinusitis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 6, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Product related serious adverse events from baseline visit to 4 weeks post procedure</measure>
    <time_frame>4 weeks post procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Mometasone Furoate concentration level from pre-treatment to end of treatment</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Sinusitis</condition>
  <arm_group>
    <arm_group_label>480 Mometasone Furoate Sinus Drug Depot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>480 Mometasone Furoate Sinus Drug Depot</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>480 Mometasone Furoate Sinus Drug Depot</intervention_name>
    <description>Management of Chronic Sinusitis</description>
    <arm_group_label>480 Mometasone Furoate Sinus Drug Depot</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CS.

          -  Female study subjects of child-bearing potential must have a negative pregnancy test
             and must agree to not become pregnant during the course of the study.

          -  The study subject has been informed of the nature of the study, agrees to its
             provisions and has provided written informed consent as approved by the ethics
             committee of the respective clinical site.

          -  The study subject agrees to comply with all study requirements

        Exclusion Criteria:

          -  Known history of intolerance to corticosteroids.

          -  Oral-steroid dependent condition.

          -  Having had corticosteroids with potential systemic effect (e.g., oral, parenteral, or
             high dose topical) 1 month prior to screening visit.

          -  Subjects with acute or chronic intracranial or orbital complications of chronic
             rhinosinusitis (e.g., brain abscess, related problems with eyes or central nervous
             system).

          -  Known history of hypothalamic pituitary adrenal (HPA) axial dysfunction or having
             morning serum cortisol level at screening outside of normal range.

          -  Previous pituitary or adrenal surgery.

          -  History or diagnosis (in either eye) of glaucoma, ocular hypertension, or cataracts.

          -  Recent participation in another clinical trial within 1 month of screening visit.

          -  Subjects currently participating in an investigational drug or device study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Center</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Auckland</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2016</study_first_submitted>
  <study_first_submitted_qc>November 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2016</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

